Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (397)

« Back to Publications

Induced pluripotent stem cell-based modelling of disease evolution in myeloid leukemia: MDS to AML.

Boultwood J., (2026), Adv Biol Regul, 99

Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolism.

Harris B. et al, (2025), Cell Rep, 44

precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery.

Roncador M. et al, (2025), Blood, 146, 1883 - 1896

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.

Aluri S. et al, (2025), J Clin Invest, 135

Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis.

Sun T. et al, (2025), Br J Haematol, 206, 1086 - 1091

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.

Borate U. et al, (2025), Blood, 145, 1369 - 1381

Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms.

Ceneri E. et al, (2025), Adv Biol Regul, 95

Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.

Pellagatti A. and Boultwood J., (2025), Adv Biol Regul, 95

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Getz T. et al, (2025), BLOOD, 146, 3852 - 3854

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).

Aakash F. et al, (2024), Mod Pathol, 37

Molecular taxonomy of myelodysplastic syndromes and its clinical implications.

Bernard E. et al, (2024), Blood, 144, 1617 - 1632

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Sirenko M. et al, (2024), Blood, 144, 1221 - 1229

Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow.

Gerlevik S. et al, (2024), Elife, 13

Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow

Gerlevik S. et al, (2024), eLife, 13

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Efficace F. et al, (2024), Hemasphere, 8

Load More

1
2
3
4
5
6
7
...
»